Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 6 340 ILS 0.32% Market Closed
Market Cap: 71.4B ILS
Have any thoughts about
Teva Pharmaceutical Industries Ltd?
Write Note
TEVA
/
Income Statement
/
Revenue

Teva Pharmaceutical Industries Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Teva Pharmaceutical Industries Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Revenue
$16.3B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Revenue
$11.7m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Revenue
₪355.6m
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
45%
Mediwound Ltd
NASDAQ:MDWD
Revenue
$20.1m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
72%
S
Seach Medical Group Ltd
TASE:SEMG
Revenue
₪162.4m
CAGR 3-Years
61%
CAGR 5-Years
66%
CAGR 10-Years
64%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Revenue
₪324.4m
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
2%
No Stocks Found

Teva Pharmaceutical Industries Ltd
Revenue Breakdown

Breakdown by Geography
Teva Pharmaceutical Industries Ltd

Not Available

Breakdown by Segments
Teva Pharmaceutical Industries Ltd

Total Revenue: 15.8B USD
100%
Product: 13B USD
81.9%
North America Segment: 8.1B USD
51.3%
Europe Segment: 4.8B USD
30.5%
International Markets: 2B USD
12.4%
Distribution Service: 1.6B USD
10.2%
Generics Medicians: 1.6B USD
10.1%
Anda: 1.6B USD
10%
Austedo: 1.2B USD
7.7%
Other Activities: 926m USD
5.8%
License: 681m USD
4.3%
Product And Service, Other: 570m USD
3.6%
Other Products: 281m USD
1.8%
Respiratory Product: 265m USD
1.7%
Bendeka And Treanda: 241m USD
1.5%
Ajovy: 44m USD
0.3%
Copaxone: 39m USD
0.2%
Show More
Show Less

Teva Pharmaceutical Industries Ltd
Glance View

Market Cap
71.4B ILS
Industry
Pharmaceuticals

Teva Pharmaceutical Industries Ltd., a pivotal player in the global pharmaceutical landscape, has carved out its niche as one of the world's largest generic drug manufacturers. Founded in 1901 and headquartered in Petah Tikva, Israel, Teva has grown through a series of strategic acquisitions and robust research and development initiatives, thereby establishing a diverse portfolio that includes both generic medications and innovative biopharmaceuticals. The company is particularly known for its vast offerings in pain management, central nervous system disorders, and respiratory therapies, positioning itself as a vital resource for accessible healthcare solutions around the globe. With operations in over 60 countries and a commitment to providing affordable medications, Teva plays a significant role in expanding the reach of essential treatments, driving patient adherence and improving health outcomes. However, Teva's journey has not been without challenges. The company has faced various headwinds, including increasing competition in the generic market, pricing pressures, and legal battles related to opioid litigations. Investors should note that Teva is currently focused on restructuring efforts to enhance operational efficiency and strengthen its balance sheet. While navigating these complexities, the company also invests in innovative drug development, aiming to diversify its pipeline and capitalize on high-growth therapeutic areas. Teva's forward-looking strategies offer an intriguing investment proposition, as they combine the potential for stability through generics with the growth opportunities found in its specialty pharmaceuticals, making it a compelling option for those looking to invest in the evolving pharmaceutical sector.

TEVA Intrinsic Value
5 822.4 ILS
Overvaluation 8%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Teva Pharmaceutical Industries Ltd's Revenue?
Revenue
16.3B USD

Based on the financial report for Jun 30, 2024, Teva Pharmaceutical Industries Ltd's Revenue amounts to 16.3B USD.

What is Teva Pharmaceutical Industries Ltd's Revenue growth rate?
Revenue CAGR 10Y
-2%

Over the last year, the Revenue growth was 8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.